A PSMA-targeting radioligand, Lutetium (177Lu) DGUL, with the anti-PD-1 therapy Keytruda (pembrolizumab) is being investigated in patients with advanced prostate cancer.
The phase 1 trial will enroll approximately 30 taxane-naïve, treatment-resistant prostate cancer patients, who will receive either Lu-177-DGUL alone or in combination with Keytruda.
The primary focus is on safety, with progression-free and overall survival as key secondary endpoints. If successful, the collaboration aims to accelerate development efforts and expand into a phase 2 combination study in the U.S. Concurrently, a separate phase 2 trial of Lu-177-DGUL in Korea is nearing completion, with final enrollment expected in the first half of the year and results anticipated by year-end.
